{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:52:50Z","timestamp":1777956770056,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00259-019-04594-z","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T15:57:18Z","timestamp":1575302238000},"page":"1927-1937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetic evaluation of [18F]PR04.MZ for PET\/CT imaging and quantification of dopamine transporters in the human brain"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5285-6447","authenticated-orcid":false,"given":"Vasko","family":"Kramer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Juri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Riss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Pruzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Soza-Ried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"R\u00f6sch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Chana-Cuevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horacio","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,1]]},"reference":[{"issue":"9","key":"4594_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.tips.2013.07.005","volume":"34","author":"RA Vaughan","year":"2013","unstructured":"Vaughan RA, Foster JD. Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci. 2013;34(9):489\u201396.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"4594_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.taap.2004.08.013","volume":"204","author":"MJ Bannon","year":"2005","unstructured":"Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease. Toxicol Appl Pharmacol. 2005;204(3):355\u201360.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"4594_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/mds.26907","volume":"32","author":"AP Strafella","year":"2017","unstructured":"Strafella AP, Bohnen NI, Perlmutter JS, et al. Molecular imaging to track Parkinson\u2019s disease and atypical parkinsonisms: New imaging frontiers. Mov Disord. 2017;32(2):181\u201392.","journal-title":"Mov Disord"},{"issue":"12","key":"4594_CR4","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","volume":"8","author":"DW Dickson","year":"2009","unstructured":"Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria. Lancet Neurol. 2009;8(12):1150\u20137.","journal-title":"Lancet Neurol"},{"issue":"7","key":"4594_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/sj.jcbfm.9600439","volume":"27","author":"M Yaqub","year":"2007","unstructured":"Yaqub M, Boellaard R, van Berckel BN, et al. Quantification of dopamine transporter binding using [18F]FP-beta-CIT and positron emission tomography. J Cereb Blood Flow Metab. 2007;27(7):1397\u2013406.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7","key":"4594_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2967\/jnumed.111.101626","volume":"53","author":"T Sasaki","year":"2012","unstructured":"Sasaki T, Ito H, Kimura Y, et al. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. J Nucl Med. 2012;53(7):1065\u201373.","journal-title":"J Nucl Med"},{"issue":"3","key":"4594_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.nucmedbio.2013.12.013","volume":"41","author":"JA Nye","year":"2014","unstructured":"Nye JA, Votaw JR, Bremmer JD, et al. Quantification of dopamine transporter density with [18F]FECNT PET in healthy humans. Nucl Med Biol. 2014;41(3):217\u201322.","journal-title":"Nucl Med Biol"},{"issue":"9","key":"4594_CR8","first-page":"1521","volume":"39","author":"K Kazumata","year":"1998","unstructured":"Kazumata K, Dhawan V, Chaly T, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39(9):1521\u201330.","journal-title":"J Nucl Med"},{"issue":"suppl 1","key":"4594_CR9","first-page":"276","volume":"58","author":"N Ariclot","year":"2017","unstructured":"Ariclot N, Vercouillie J, Malherbe C, et al. PET imaging of dopamine transporter with 18F-LBT999: first human exploration. J Nucl Med. 2017;58(suppl 1):276.","journal-title":"J Nucl Med"},{"issue":"7","key":"4594_CR10","doi-asserted-by":"publisher","first-page":"e22032","DOI":"10.1002\/syn.22032","volume":"72","author":"I Lee","year":"2018","unstructured":"Lee I, Kim JS, Park JY, et al. Head-to-head comparison of 18F-FP-CIT and 123I-FP-CIT for dopamine transporter imaging in patients with Parkinson\u2019s disease: a preliminary study. Synapse. 2018;72(7):e22032.","journal-title":"Synapse"},{"issue":"1","key":"4594_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13550-018-0450-0","volume":"8","author":"S Jakobson Mo","year":"2018","unstructured":"Jakobson Mo S, Axelsson J, Jonasson L, et al. Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT-a clinical comparison. EJNMMI Res. 2018;8(1):100.","journal-title":"EJNMMI Res"},{"issue":"13","key":"4594_CR12","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1039\/b902863c","volume":"7","author":"PJ Riss","year":"2009","unstructured":"Riss PJ, Hummerich R, Schloss P. Synthesis and monoamine uptake inhibition of conformationally constrained 2beta-carbomethoxy-3beta-phenyl tropanes. Org Biomol Chem. 2009;7(13):2688\u201398.","journal-title":"Org Biomol Chem"},{"issue":"9","key":"4594_CR13","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/cmdc.200900177","volume":"4","author":"PJ Riss","year":"2009","unstructured":"Riss PJ, Debus F, Hummerich R, et al. Ex vivo and in vivo evaluation of [18F]PR04.MZ in rodents: a selective dopamine transporter imaging agent. ChemMedChem. 2009;4(9):1480\u20137.","journal-title":"ChemMedChem"},{"issue":"1","key":"4594_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0969-8051(99)00080-3","volume":"27","author":"MM Goodman","year":"2000","unstructured":"Goodman MM, Kilts CD, Keil R, et al. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol. 2000;27(1):1\u201312.","journal-title":"Nucl Med Biol"},{"issue":"1","key":"4594_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1124\/jpet.105.096792","volume":"317","author":"S Chalon","year":"2006","unstructured":"Chalon S, Hall H, Saba W, et al. Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4\u2032-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter. J Pharmacol Exp Ther. 2006;317(1):147\u201352.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"4594_CR16","first-page":"648","volume":"291","author":"S Chalon","year":"1999","unstructured":"Chalon S, Garreau L, Emond P, et al. Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4\u2032-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther. 1999;291(2):648\u201354.","journal-title":"J Pharmacol Exp Ther"},{"issue":"22","key":"4594_CR17","doi-asserted-by":"publisher","first-page":"7630","DOI":"10.1016\/j.bmc.2009.09.054","volume":"17","author":"PJ Riss","year":"2009","unstructured":"Riss PJ, Roesch F. Efficient microwave-assisted direct radiosynthesis of [18F]PR04.MZ and [18F]LBT999: selective dopamine transporter ligands for quantitative molecular imaging by means of PET. Bioorg Med Chem. 2009;17(22):7630\u20134.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"4594_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.bmcl.2011.10.053","volume":"22","author":"PJ Riss","year":"2012","unstructured":"Riss PJ, Hooker JM, Shea C, et al. Characterisation of [11C]PR04.MZ in Papio anubis baboon: a selective high-affinity radioligand for quantitative imaging of the dopamine transporter. Bioorg Med Chem Lett. 2012;22(1):679\u201382.","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"4594_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/RLU.0000000000000868","volume":"40","author":"C Juri","year":"2015","unstructured":"Juri C, Chana P, Kramer V, et al. Imaging nigrostriatal dopaminergic deficit in Holmes tremor with 18F-PR04.MZ-PET\/CT. Clin Nucl Med. 2015;40(9):740\u20131.","journal-title":"Clin Nucl Med"},{"issue":"suppl 1","key":"4594_CR20","first-page":"1829","volume":"55","author":"V Kramer","year":"2014","unstructured":"Kramer V, Juri C, Chana-Cuevas P, et al. Dopamine transporter quantification by PET with [18F]PR04.MZ in patients with early Parkinson\u2019s disease. J Nucl Med. 2014;55(suppl 1):1829.","journal-title":"J Nucl Med"},{"issue":"suppl 2","key":"4594_CR21","first-page":"416","volume":"54","author":"V Kramer","year":"2013","unstructured":"Kramer V, Pruzzo R, Chana-Cuevas P, et al. Initial human PET studies with [18F]PR04.MZ for quantification of striatal and extrastriatal dopamine transporters. J Nucl Med. 2013;54(suppl 2):416.","journal-title":"J Nucl Med"},{"issue":"4","key":"4594_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hbm.10123","volume":"19","author":"A Hammers","year":"2003","unstructured":"Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224\u201347.","journal-title":"Hum Brain Mapp"},{"key":"4594_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/00004647-199601000-00005","volume":"16","author":"AA Lammertsma","year":"1996","unstructured":"Lammertsma AA, Bench CJ, Hume SP, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab. 1996;16:10.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"4594_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1006\/nimg.1996.0066","volume":"4","author":"AA Lammertsma","year":"1996","unstructured":"Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. NeuroImage. 1996;4(3):153\u20138.","journal-title":"NeuroImage"},{"issue":"1","key":"4594_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13550-018-0366-8","volume":"8","author":"R Baumgartner","year":"2018","unstructured":"Baumgartner R, Joshi A, Feng D, Zanderigo F, Ogden RT. Statistical evaluation of test-retest studies in PET brain imaging. EJNMMI Res. 2018;8(1):13.","journal-title":"EJNMMI Res"},{"key":"4594_CR26","doi-asserted-by":"crossref","unstructured":"Darcourt J, Booij J, Tatsch K et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37(2):443\u201350.","DOI":"10.1007\/s00259-009-1267-x"},{"issue":"2","key":"4594_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155\u201363.","journal-title":"J Chiropr Med"},{"key":"4594_CR28","unstructured":"Chana-Cuevas P, Juri C, Kramer V et al. 2016 Quantification of striatal dopamine transporters with [18F]PR04.MZ in patients with progressive supranuclear palsy and Parkinson\u2019s disease. Mov Disord.;31(suppl 2). https:\/\/www.mdsabstracts.org\/abstract\/quantification-of-striatal-dopamine-transporters-with-18fpr04-mz-in-patients-with-progressive-supranuclear-palsy-and-parkinsons-disease\/."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04594-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04594-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04594-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:07:30Z","timestamp":1606694850000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04594-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4594"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04594-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,1]]},"assertion":[{"value":"8 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the regional ethics committee board (CEC SSM Oriente, permit 20140520) and written informed consent has been obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}